The North America atrial fibrillation market is expected to reach US$ 6,284.87 Mn by 2027 from US$ 2,285.69 Mn in 2019 The market is estimated to grow at a CAGR of 13.7% from 2020 to 2027.
The atrial fibrillation market is growing primarily due to rising number of patients suffering with cardiovascular diseases, and rising awareness regarding atrial fibrillation. Restraining factor such as high cost of atrial fibrillation devices and procedures is likely to have negative impact on the growth of the market in the coming years.
Growth opportunities in the developing nations have always had major impact in the field of medicine. The rise in the cardiovascular conditions are rising across the globe, the prevalence is significantly rising in the countries of the developing nations. The incidences are rising due to the shift in the lifestyle and the other health conditions due to the change in the adoption of the modernized facilities. The modernized facilities reduced the physical activities, and the stress level among the people is also growing. Thus, these factors are leading to the cardiovascular conditions and is leading to the rising demand for the atrial fibrillation treatment.
The developing nations are significantly developing their healthcare facilities and services and are heading towards the technological advancements. For instance, structural heart is at initial stage of the development in the regions like Asia Pacific and Middle East and Africa.
For instance, in India KIM hospital provides services for the heart conditions in the south Indian region. In addition, the incidences of the AF is increasing in the North American countries. As per the report Epidemiology of AF 2019, by Biosense Webster, every year around 1.4 million new people suffer from AF. Also, according to the statistics it is expected that the incidences for the heart diseases are likely to increase in the Asian region.
Thus, the opportunities for the market players to enter the market with the cost effective products are higher. Therefore, owing to the above mentioned factors the growth of the market is likely to boost in these regions during the forecasted period.
Some of the significant primary and secondary sources for RTLS for Healthcare included in the report are World Health Organization (WHO), Cardiac Research Center, Japanese Association of Healthcare Information Systems, and others.
Reasons to Buy:
The atrial fibrillation market is growing primarily due to rising number of patients suffering with cardiovascular diseases, and rising awareness regarding atrial fibrillation. Restraining factor such as high cost of atrial fibrillation devices and procedures is likely to have negative impact on the growth of the market in the coming years.
Growth opportunities in the developing nations have always had major impact in the field of medicine. The rise in the cardiovascular conditions are rising across the globe, the prevalence is significantly rising in the countries of the developing nations. The incidences are rising due to the shift in the lifestyle and the other health conditions due to the change in the adoption of the modernized facilities. The modernized facilities reduced the physical activities, and the stress level among the people is also growing. Thus, these factors are leading to the cardiovascular conditions and is leading to the rising demand for the atrial fibrillation treatment.
The developing nations are significantly developing their healthcare facilities and services and are heading towards the technological advancements. For instance, structural heart is at initial stage of the development in the regions like Asia Pacific and Middle East and Africa.
For instance, in India KIM hospital provides services for the heart conditions in the south Indian region. In addition, the incidences of the AF is increasing in the North American countries. As per the report Epidemiology of AF 2019, by Biosense Webster, every year around 1.4 million new people suffer from AF. Also, according to the statistics it is expected that the incidences for the heart diseases are likely to increase in the Asian region.
Thus, the opportunities for the market players to enter the market with the cost effective products are higher. Therefore, owing to the above mentioned factors the growth of the market is likely to boost in these regions during the forecasted period.
Some of the significant primary and secondary sources for RTLS for Healthcare included in the report are World Health Organization (WHO), Cardiac Research Center, Japanese Association of Healthcare Information Systems, and others.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America Atrial Fibrillation market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America atrial fibrillation market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. North America Atrial Fibrillation Market - Market Landscape
5. North America Atrial Fibrillation Market- Key Market Dynamics
6. Atrial Fibrillation Market - North America Analysis
7. North America Atrial Fibrillation Market Analysis - By Treatment Type
8. North America Atrial Fibrillation Market Analysis - By End User
9. Atrial Fibrillation Market -Industry Landscape
10. Atrial Fibrillation Market- Key Company Profiles
11. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Boston Scientific Corporation
- Medtronic
- AtriCure, Inc
- BOEHRINGER INGELHEIM GMBH, Inc
- CardioFocus
- Abbott
- Sanofi
- Bristol-Myers Squibb Company
- Biotronik, Inc
- Biosense Webster, Inc.
